RA Capital Management 13F holdings, Q1 2012
Holdings as of March 31, 2012 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 23 US equity positions worth $184.6m in its Q1 2012 13F filing. The largest position was SEQUENOM INC at 12.2% of the reported book, followed by ARTHROCARE CORP and POZEN INC. Against the Q4 2011 filing, it opened 12 new positions, added to 4 and reduced 5 among the top 23 holdings.
What did RA Capital Management own in Q1 2012? Top 23 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2011 |
|---|---|---|---|---|---|---|---|
| 1 | SEQUENOM INC | 12.2% | $22.6m | 5,547,283 | -9% | reduced | |
| 2 | ARTHROCARE CORP | 9.9% | $18.3m | 683,146 | 60% | added | |
| 3 | POZEN INC | 9.6% | $17.7m | 2,946,944 | 21% | added | |
| 4 | XOMA CORP DEL | 8.1% | $15.0m | 5,426,009 | – | new | |
| 5 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 8.0% | $14.7m | 3,045,146 | – | new |
| 6 | VNDA VANDA PHARMACEUTICALS INC | Healthcare | 6.7% | $12.3m | 2,573,570 | 6% | added |
| 7 | DYAX CORP | 6.5% | $12.1m | 7,736,875 | 25% | added | |
| 8 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 6.1% | $11.3m | 5,269,999 | 0% | held |
| 9 | DERMA SCIENCES INC | 5.4% | $10.0m | 1,043,419 | 0% | held | |
| 10 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 3.7% | $6.8m | 850,000 | – | new |
| 11 | VIVUS INC | 3.6% | $6.7m | 300,000 | – | new | |
| 12 | VSTM VERASTEM INC | Healthcare | 3.6% | $6.6m | 605,600 | – | new |
| 13 | VENTRUS BIOSCIENCES INC | 2.9% | $5.3m | 534,916 | -39% | reduced | |
| 14 | ANACOR PHARMACEUTICALS INC | 2.6% | $4.7m | 800,530 | – | new | |
| 15 | YM BIOSCIENCES INC | 2.3% | $4.3m | 2,288,000 | – | new | |
| 16 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 1.9% | $3.5m | 705,679 | -19% | reduced |
| 17 | ARDEA BIOSCIENCES INC | 1.8% | $3.3m | 150,010 | – | new | |
| 18 | REPROS THERAPEUTICS INC | 1.5% | $2.8m | 666,666 | – | new | |
| 19 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 1.5% | $2.8m | 250,000 | – | new |
| 20 | NEWLINK GENETICS CORP | 1.4% | $2.6m | 288,456 | -42% | reduced | |
| 21 | PAIN THERAPEUTICS INC | 0.2% | $424.0k | 117,084 | – | new | |
| 22 | NVAX NOVAVAX INC | Healthcare | 0.2% | $378.0k | 300,000 | -69% | reduced |
| 23 | CORONADO BIOSCIENCES INC | 0.2% | $353.0k | 41,700 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.